Bankrupt drugmaker Mallinckrodt is in talks with major investors about selling some or all of its business units, which could lead to its exit from the opioid business, the Wall Street Journal reported on Monday, citing people familiar with the discussions. Some investors, poised to take control through the company's ongoing bankruptcy proceedings, are suggesting Mallinckrodt break up its business units, the report said. Mallinckrodt did not immediately respond to a Reuters request for comment...

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24. U.S.-based drugmakers Mallinckrodt and Viatris , UK-based Hikma Pharmaceuticals and Indian drugmaker Sun Pharmaceutical Industries confi...

Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, 2023 from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Lisdexamfetamine Dimesylate Capsules 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg. The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RL

Mallinckrodt plc (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023.

Drugmaker Mallinckrodt on Monday filed for its second bankruptcy in three years in the United States, with a restructuring plan that would cut $1 billion from what it owes to victims of the opioid crisis. The New York Stock Exchange said it has suspended trading in Mallinckrodt's ordinary shares with immediate effect and has commenced proceedings to delist them from the exchange. Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its hig...

Drugmaker Mallinckrodt on Monday filed for its second bankruptcy in three years in the United States, with a restructuring plan that would cut $1 billion from what it owes to victims of the opioid crisis. The New York Stock Exchange said it has suspended trading in Mallinckrodt's ordinary shares with immediate effect and has commenced proceedings to delist them from the exchange. Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its hig...

Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust"), as announced on August 23, 2023.

The following are the top stories in the Wall Street Journal. - Woodside Energy reached a preliminary deal with disaffected workers at some of its natural gas export facilities in Australia, a move that could head off a walkout that risked disrupting global gas supply and jolting worldwide energy prices. - Shortly after 6 p.m. Moscow time on Wednesday, an Embraer jet carrying Wagner paramilitary group owner Yevgeny Prigozhin, who led a short-lived June uprising that challenged Russian Presiden...

The following are the top stories on the New York Times business pages. - Mark Thompson, a former top executive at The New York Times and the BBC, is one of several people in talks to lead CNN. - Drugmaker Mallinckrodt said on Wednesday it expects to file for a second bankruptcy in the coming days, after reaching a debt reduction deal that would cut $1 billion from the amount it owes to victims of the opioid crisis.

Mallinckrodt agreed to hand lenders control of the pharmaceutical company through its second bankruptcy filing in three years while reducing by roughly $1 billion the settlement payments it had pledged for its alleged role in the opioid crisis.